These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 26666910)

  • 1. [Non-interventional study for the treatment of neutropenia: Use of pegfilgrastim for chemotherapy-induced neutropenia].
    Wülfing C; Rexer H
    Urologe A; 2016 Jan; 55(1):76-7. PubMed ID: 26666910
    [No Abstract]   [Full Text] [Related]  

  • 2. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
    Bhana N
    Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegfilgrastim prophylaxis for cladribine-induced neutropenia in patients with hairy-cell leukemia.
    Goldschmidt N; Ganzel C; Attias D; Gatt M; Polliack A; Tadmor T
    Acta Haematol; 2014; 132(1):118-21. PubMed ID: 24557414
    [No Abstract]   [Full Text] [Related]  

  • 4. Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia.
    Ricotta R; Cerea G; Schiavetto I; Maugeri MR; Pedrazzoli P; Siena S
    Future Oncol; 2006 Dec; 2(6):667-76. PubMed ID: 17155894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.
    Weycker D; Malin J; Barron R; Edelsberg J; Kartashov A; Oster G
    Am J Clin Oncol; 2012 Jun; 35(3):267-74. PubMed ID: 21378538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of a new formulation of lenograstim (recombinant glycosylated human granulocyte colony-stimulating factor) containing gelatin for the treatment of neutropenia after consolidation chemotherapy in patients with acute myeloid leukemia.
    Takeshita A; Saito H; Toyama K; Horiuchi A; Kuriya S; Furusawa S; Tsuruoka N; Takiguchi T; Matsuda T; Utsumi M; Shiku H; Matsui T; Egami K; Tamura K; Ohno R
    Int J Hematol; 2000 Feb; 71(2):136-43. PubMed ID: 10745623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desensitization to lenograstim after a life- threatening reaction to filgrastim.
    Nuñez-Acevedo B; Rodríguez-Jiménez B; Domínguez-Ortega J; González-Montellano E; Ibáñez-Heras N; Enrech-Francés S
    J Investig Allergol Clin Immunol; 2015; 25(2):158-60. PubMed ID: 25997320
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutic administration of pegfilgrastim instead of prophylactic use.
    Stathopoulos GP; Dimou E; Stathopoulos J; Xynotroulas J
    Anticancer Res; 2005; 25(3c):2445-8. PubMed ID: 16080473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Introduction: pegfilgrastim, a new era in the management of chemotherapy-induced neutropenia.
    Petros WP
    Pharmacotherapy; 2003 Aug; 23(8 Pt 2):1S-2S; quiz 20S-23S. PubMed ID: 12921215
    [No Abstract]   [Full Text] [Related]  

  • 10. Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients: randomized controlled trial.
    Paul M; Ram R; Kugler E; Farbman L; Peck A; Leibovici L; Lahav M; Yeshurun M; Shpilberg O; Herscovici C; Wolach O; Itchaki G; Bar-Natan M; Vidal L; Gafter-Gvili A; Raanani P
    Am J Hematol; 2014 Mar; 89(3):243-8. PubMed ID: 24178750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegfilgrastim -- rational drug design for the management of chemotherapy-induced neutropenia.
    Lüftner D; Possinger K
    Onkologie; 2005 Nov; 28(11):595-602. PubMed ID: 16249646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegfilgrastim: a review of the pharmacoeconomics for chemotherapy-induced neutropenia.
    Rofail P; Tadros M; Ywakim R; Tadrous M; Krug A; Cosler LE
    Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):699-709. PubMed ID: 23252353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of low-dose versus standard-dose colony stimulating factor in patients with chemotherapy-induced febrile neutropenia.
    Burney IA; Salam A; Jat AA; Iqbal MP; Siddiqui T; Khan MA; Smego RA
    Oncology; 2003; 65(3):283-4. PubMed ID: 14657603
    [No Abstract]   [Full Text] [Related]  

  • 14. Low-dose filgrastim therapy for chronic neutropenia.
    Kaczmarski RS; Mufti GJ
    N Engl J Med; 1993 Oct; 329(17):1280-1. PubMed ID: 7692296
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
    Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
    Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.
    Vose JM; Crump M; Lazarus H; Emmanouilides C; Schenkein D; Moore J; Frankel S; Flinn I; Lovelace W; Hackett J; Liang BC
    J Clin Oncol; 2003 Feb; 21(3):514-9. PubMed ID: 12560443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
    Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I
    Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies.
    Whitworth JM; Matthews KS; Shipman KA; Numnum TM; Kendrick JE; Kilgore LC; Straughn JM
    Gynecol Oncol; 2009 Mar; 112(3):601-4. PubMed ID: 19110303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses.
    Henk HJ; Becker L; Tan H; Yu J; Kavati A; Naeim A; Deeter R; Barron R
    J Med Econ; 2013; 16(1):160-8. PubMed ID: 23016568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia.
    Ghalaut PS; Sen R; Dixit G
    J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.